From the data on every profile
FDA-approved peptides and longevity compounds
Written by Aaron CuhaReviewed 26 Sep 2026
83 of the 453 compounds in this archive are approved medicines in the United States. 9 more reach people only through a prescriber or a compounding pharmacy, and 108 are in registered trials with no approval. Everything else is not approved for any use in people, whatever the vial label says.
Generated from the US classification on each profile at build time, so this list and the profiles cannot disagree. Approval covers a labeled indication; it is not a statement that a compound works for anything else, and it is not clearance for sport.
Approved medicine 83
| Compound | US classification | Human studies cited | Band |
|---|---|---|---|
| AbaloparatideHormone | FDA-approved, prescription only US page | 2 | Moderate. At least one completed trial, and at least 100 people given it. 1 completed trial, 2,463 people given it. |
| AcarboseLongevity | Prescription only; approved for type 2 diabetes US page | 2 | Preliminary. Studied in people, but no published study has given it to anyone. 2 human studies where nobody was given it. |
| Angiotensin IIHormone | FDA-approved, prescription only US page | 5 | Moderate. At least one completed trial, and at least 100 people given it. 1 completed trial, 344 people given it. |
| Azithromycin and roxithromycinAnti-aging | FDA-approved, prescription only US page | 2 | Moderate. At least one completed trial, and at least 100 people given it. 1 completed trial, 480 people given it. |
| Botulinum toxin type ACosmetic | FDA-approved, prescription only US page | 3 | Strong. At least two completed trials, and at least 1,000 people given it. 2 completed trials, 1,681 people given it. |
| CalcitoninHormone | FDA-approved, prescription only US page | 1 | Preliminary. Studied in people, but no published study has given it to anyone. 1 human study where nobody was given it. |
| Cardiac glycosidesLongevity | FDA-approved, prescription only US page | 2 | Moderate. At least one completed trial, and at least 100 people given it. 1 completed trial, 6,800 people given it. |
| CetrorelixHormone | FDA-approved, prescription only US page | 2 | Moderate. At least one completed trial, and at least 100 people given it. 1 completed trial, 564 people given it. |
| DanazolHormone | FDA-approved, prescription only US page | 5 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 3 completed trials, 63 people given it. |
| DasatinibLongevity | FDA-approved (for its labeled use), prescription only US page | 4 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 3 completed trials, 74 people given it. |
| DegarelixHormone | FDA-approved, prescription only US page | 3 | Moderate. At least one completed trial, and at least 100 people given it. 2 completed trials, 610 people given it. |
| DesmopressinHormone | FDA-approved, prescription only US page | 2 | Moderate. At least one completed trial, and at least 100 people given it. 1 completed trial, 261 people given it. |
| Dimethyl fumarateAntioxidant | FDA-approved, prescription only US page | 3 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 3 completed trials, 54 people given it. |
| DulaglutideMetabolic | FDA-approved, prescription only US page | 2 | Strong. At least two completed trials, and at least 1,000 people given it. 2 completed trials, 10,500 people given it. |
| ElamipretideAnti-aging | FDA-approved (Forzinity, Barth syndrome only), prescription only; other uses investigational US page | 5 | Moderate. At least one completed trial, and at least 100 people given it. 5 completed trials, 487 people given it. |
| EmpagliflozinMetabolic | FDA-approved, prescription only US page | 4 | Strong. At least two completed trials, and at least 1,000 people given it. 3 completed trials, 16,738 people given it. |
| EnalaprilLongevity | FDA-approved, prescription only US page | 3 | Strong. At least two completed trials, and at least 1,000 people given it. 2 completed trials, 2,822 people given it. |
| EnlicitideMetabolic | Prescription only; FDA approved US page | 3 | Strong. At least two completed trials, and at least 1,000 people given it. 3 completed trials, 2,909 people given it. |
| ErythropoietinHormone | FDA-approved, prescription only US page | 4 | Strong. At least two completed trials, and at least 1,000 people given it. 3 completed trials, 4,641 people given it. |
| EverolimusLongevity | FDA-approved, prescription only US page | 3 | Strong. At least two completed trials, and at least 1,000 people given it. 3 completed trials, 1,024 people given it. |
| ExenatideMetabolic | FDA-approved, prescription only US page | 2 | Strong. At least two completed trials, and at least 1,000 people given it. 2 completed trials, 15,088 people given it. |
| GlucagonMetabolic | FDA-approved, prescription only US page | 2 | Moderate. At least one completed trial, and at least 100 people given it. 2 completed trials, 141 people given it. |
| GoserelinHormone | FDA-approved, prescription only US page | 2 | Preliminary. Studied in people, but no published study has given it to anyone. 2 human studies where nobody was given it. |
| HCGHormone | FDA-approved, prescription only US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 2 completed trials, 55 people given it. |
| HydralazineLongevity | FDA-approved, prescription only US page | 3 | Strong. At least two completed trials, and at least 1,000 people given it. 3 completed trials, 1,724 people given it. |
| IcatibantHormone | FDA-approved, prescription only US page | 5 | Moderate. At least one completed trial, and at least 100 people given it. 5 completed trials, 306 people given it. |
| IcotrokinraImmune | Prescription only; FDA approved US page | 2 | Moderate. At least one completed trial, and at least 100 people given it. 2 completed trials, 311 people given it. |
| InsulinMetabolic | FDA-approved, prescription only US page | 8 | Strong. At least two completed trials, and at least 1,000 people given it. 5 completed trials, 29,691 people given it. |
| L-CarnitineMuscle & Performance | FDA-approved for deficiency; also sold as a supplement US page | 1 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| LamivudineAnti-aging | FDA-approved, prescription only US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| LanreotideHormone | FDA-approved, prescription only US page | 1 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| LeptinMetabolic | FDA-approved, prescription only US page | 7 | Moderate. At least one completed trial, and at least 100 people given it. 6 completed trials, 844 people given it. |
| LeuprolideHormone | FDA-approved, prescription only US page | 2 | Moderate. At least one completed trial, and at least 100 people given it. 2 completed trials, 199 people given it. |
| LinaclotideHealing & Recovery | FDA-approved, prescription only US page | 1 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| LiraglutideMetabolic | FDA-approved, prescription only US page | 6 | Strong. At least two completed trials, and at least 1,000 people given it. 6 completed trials, 16,760 people given it. |
| LixisenatideMetabolic | FDA-approved, prescription only US page | 2 | Strong. At least two completed trials, and at least 1,000 people given it. 2 completed trials, 6,068 people given it. |
| MecaserminGrowth Hormone | FDA-approved, prescription only US page | 5 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, 76 people given it. |
| Melanotan IMelanocortin | FDA-approved for a specific indication, prescription only US page | 6 | Moderate. At least one completed trial, and at least 100 people given it. 2 completed trials, 170 people given it. |
| MetforminLongevity | Prescription only; approved for type 2 diabetes US page | 7 | Moderate. At least one completed trial, and at least 100 people given it. 3 completed trials, 489 people given it. |
| MethotrexateImmune | FDA-approved, prescription only US page | 2 | Strong. At least two completed trials, and at least 1,000 people given it. 2 completed trials, 5,022 people given it. |
| Methylene BlueAntioxidant | Prescription drug for methemoglobinemia; 'supplement' products are unapproved US page | 3 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, 26 people given it. |
| MetreleptinHormone | FDA-approved, prescription only US page | 1 | Preliminary. Studied in people, but no published study has given it to anyone. 1 human study where nobody was given it. |
| MifepristoneHormone | FDA-approved, prescription only US page | 2 | Moderate. At least one completed trial, and at least 100 people given it. 2 completed trials, 320 people given it. |
| MinocyclineLongevity | FDA-approved, prescription only US page | 2 | Moderate. At least one completed trial, and at least 100 people given it. 2 completed trials, 966 people given it. |
| Mycophenolic acidImmune | FDA-approved, prescription only US page | 2 | Moderate. At least one completed trial, and at least 100 people given it. 2 completed trials, 227 people given it. |
| NACAntioxidant | FDA-approved drug and sold as a supplement US page | 3 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 2 completed trials, 15 people given it. |
| NavepegritideHormone | FDA-approved (achondroplasia), prescription only US page | 2 | Preliminary. Studied in people, but no published study has given it to anyone. 2 human studies where nobody was given it. |
| NiacinLongevity | FDA-approved prescription lipid drug, also sold over the counter as a supplement US page | 5 | Strong. At least two completed trials, and at least 1,000 people given it. 2 completed trials, 29,087 people given it. |
| OctreotideHormone | FDA-approved, prescription only US page | 2 | Moderate. At least one completed trial, and at least 100 people given it. 2 completed trials, 140 people given it. |
| OrforglipronMetabolic | FDA-approved (Foundayo, chronic weight management), prescription only US page | 11 | Strong. At least two completed trials, and at least 1,000 people given it. 8 completed trials, 17,383 people given it. |
| OveporextonNootropic & CNS | FDA-approved, prescription only US page | 6 | Moderate. At least one completed trial, and at least 100 people given it. 6 completed trials, 441 people given it. |
| OxandroloneMuscle & Performance | Approved indication exists; brand discontinued. Schedule III US page | 1 | Preliminary. Studied in people, but no published study has given it to anyone. 1 human study where nobody was given it. |
| OxytocinHormone | FDA-approved, prescription only US page | 2 | Moderate. At least one completed trial, and at least 100 people given it. 2 completed trials, 290 people given it. |
| PegcetacoplanImmune | FDA-approved, prescription only US page | 4 | Strong. At least two completed trials, and at least 1,000 people given it. 3 completed trials, 1,258 people given it. |
| PioglitazoneMetabolic | FDA-approved, prescription only US page | 2 | Strong. At least two completed trials, and at least 1,000 people given it. 2 completed trials, 9,114 people given it. |
| PlecanatideHealing & Recovery | FDA-approved, prescription only US page | 2 | Strong. At least two completed trials, and at least 1,000 people given it. 2 completed trials, 1,337 people given it. |
| PramlintideMetabolic | FDA-approved, prescription only US page | 4 | Moderate. At least one completed trial, and at least 100 people given it. 3 completed trials, 684 people given it. |
| PT-141Melanocortin | FDA-approved, prescription only US page | 4 | Strong. At least two completed trials, and at least 1,000 people given it. 4 completed trials, 2,355 people given it. |
| RapamycinLongevity | FDA-approved (for its labeled use), prescription only US page | 3 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 2 completed trials, 25 people given it. |
| RusfertideHormone | FDA-approved, prescription only US page | 7 | Moderate. At least one completed trial, and at least 100 people given it. 5 completed trials, 166 people given it. |
| RuxolitinibAnti-aging | FDA-approved, prescription only US page | 2 | Moderate. At least one completed trial, and at least 100 people given it. 1 completed trial, 309 people given it. |
| SemaglutideMetabolic | FDA-approved, prescription only US page | 15 | Strong. At least two completed trials, and at least 1,000 people given it. 12 completed trials, 42,363 people given it. |
| SetmelanotideMelanocortin | FDA-approved, prescription only US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, 38 people given it. |
| SimvastatinLongevity | FDA-approved, prescription only US page | 2 | Strong. At least two completed trials, and at least 1,000 people given it. 2 completed trials, 24,980 people given it. |
| Sodium phenylbutyrateLongevity | FDA-approved, prescription only US page | 2 | Moderate. At least one completed trial, and at least 100 people given it. 2 completed trials, 148 people given it. |
| SomatropinGrowth Hormone | FDA-approved, prescription only US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 2 completed trials, 84 people given it. |
| TeduglutideMetabolic | FDA-approved, prescription only US page | 3 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 2 completed trials, 83 people given it. |
| TeriparatideHormone | FDA-approved, prescription only US page | 2 | Moderate. At least one completed trial, and at least 100 people given it. 1 completed trial, 1,637 people given it. |
| TesamorelinGrowth Hormone | FDA-approved for a specific indication, prescription only US page | 8 | Strong. At least two completed trials, and at least 1,000 people given it. 8 completed trials, 1,729 people given it. |
| TestosteroneHormone | FDA-approved, prescription only US page | 2 | Moderate. At least one completed trial, and at least 100 people given it. 1 completed trial, 5,246 people given it. |
| Testosterone cypionateHormone | FDA-approved, prescription only US page | 1 | Moderate. At least one completed trial, and at least 100 people given it. 1 completed trial, 5,246 people given it. |
| Testosterone enanthateHormone | FDA-approved, prescription only US page | 1 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| Therapeutic Plasma ExchangeLongevity | Approved medical procedure; not approved for ageing indications US page | 7 | Moderate. At least one completed trial, and at least 100 people given it. 5 completed trials, 389 people given it. |
| TirzepatideMetabolic | FDA-approved, prescription only US page | 11 | Strong. At least two completed trials, and at least 1,000 people given it. 9 completed trials, 22,802 people given it. |
| TrametinibLongevity | FDA-approved, prescription only US page | 2 | Strong. At least two completed trials, and at least 1,000 people given it. 2 completed trials, 1,192 people given it. |
| TriptorelinHormone | FDA-approved, prescription only US page | 4 | Strong. At least two completed trials, and at least 1,000 people given it. 4 completed trials, 1,388 people given it. |
| Ursodeoxycholic acidLongevity | FDA-approved, prescription only US page | 1 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, 30 people given it. |
| VasopressinHormone | FDA-approved, prescription only US page | 2 | Moderate. At least one completed trial, and at least 100 people given it. 1 completed trial, 778 people given it. |
| Vitamin B12Metabolic | Approved for deficiency; widely available as a supplement US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 2 completed trials, none stating how many people. |
| VosoritideGrowth Hormone | FDA-approved, prescription only US page | 1 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| Young Plasma InfusionLongevity | Licensed blood component; infusion for ageing is an unapproved use US page | 3 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, 18 people given it. |
| ZiconotideNootropic & CNS | FDA-approved, prescription only US page | 2 | Moderate. At least one completed trial, and at least 100 people given it. 2 completed trials, 111 people given it. |
| Zoledronic acidLongevity | FDA-approved, prescription only US page | 4 | Strong. At least two completed trials, and at least 1,000 people given it. 4 completed trials, 7,176 people given it. |
Prescription route 9
Available through a prescriber or a compounding pharmacy without a broad marketing approval. The compounded product is not the FDA-approved product.
| Compound | US classification | Human studies cited | Band |
|---|---|---|---|
| EnclomipheneHormone | Prescription via compounding pharmacies; not FDA-approved US page | 1 | Preliminary. Studied in people, but no published study has given it to anyone. 1 human study where nobody was given it. |
| GonadorelinHormone | Prior approvals largely discontinued; available via compounding, prescription only US page | 3 | Moderate. At least one completed trial, and at least 100 people given it. 3 completed trials, 110 people given it. |
| Metformin plus rapamycinLongevity | Prescription only, each drug separately; no approved combination US page | 2 | Preliminary. Studied in people, but no published study has given it to anyone. 2 registered with no result. |
| NAD+Longevity | Not FDA-approved; compounded/IV and supplement forms marketed US page | 1 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| NAD+ with glutathioneLongevity | Sold as compounded injections and as oral supplements US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, 21 people given it. |
| Rapamycin plus acarboseLongevity | Prescription only, each drug separately; no approved combination US page | 0 | Preclinical. Animals or cells only among the studies cited here. No human study on this page. 7 animal studies, no human study. |
| SermorelinGrowth Hormone | Prior approval discontinued; available via compounding pharmacies US page | 3 | Moderate. At least one completed trial, and at least 100 people given it. 3 completed trials, 139 people given it. |
| Sermorelin / GHRPGrowth Hormone | No approved blend; sermorelin is available compounded US page | 5 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 4 completed trials, 56 people given it. |
| VerteporfinHealing & Recovery | Prescription only (approved for eye use); wound use off-label/investigational US page | 1 | Preliminary. Studied in people, but no published study has given it to anyone. 1 human study where nobody was given it. |
Investigational 108
In registered clinical trials. Lawful access is trial participation; vials sold online are not trial material.
| Compound | US classification | Human studies cited | Band |
|---|---|---|---|
| 17-DMAGLongevity | Investigational, not approved US page | 4 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 2 completed trials, 49 people given it. |
| AleniglipronMetabolic | Investigational, not approved US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| AmycretinMetabolic | Investigational, not approved US page | 3 | Moderate. At least one completed trial, and at least 100 people given it. 1 completed trial, 125 people given it. |
| Angiotensin-(1-7)Hormone | Investigational, not approved US page | 7 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 5 completed trials, 76 people given it. |
| Anti-IL-11Longevity | Investigational, not approved US page | 0 | Preclinical. Animals or cells only among the studies cited here. No human study on this page. 1 animal study, no human study. |
| ApitegromabMuscle & Performance | Investigational, not approved US page | 2 | Preliminary. Studied in people, but no published study has given it to anyone. 2 human studies where nobody was given it. |
| ApraglutideHealing & Recovery | Investigational, not approved US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 2 completed trials, none stating how many people. |
| ARA-290Healing & Recovery | Investigational, not approved US page | 6 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 5 completed trials, 95 people given it. |
| AT673Metabolic | Investigational, not approved US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| AZD6234Metabolic | Investigational, not approved US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| AzelapragMuscle & Performance | Investigational; development halted US page | 2 | Preliminary. Studied in people, but no published study has given it to anyone. 2 registered with no result. |
| BerobenatideMetabolic | Investigational, not approved US page | 3 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 3 completed trials, none stating how many people. |
| BGE-102Longevity | Investigational, not approved US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| BGM0504Metabolic | Investigational, not approved US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, 64 people given it. |
| BGM1812Metabolic | Investigational, not approved US page | 3 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| BI 1820237Metabolic | Investigational, not approved US page | 2 | Preliminary. Studied in people, but no published study has given it to anyone. 2 human studies where nobody was given it. |
| BI 3034701Metabolic | Investigational, not approved US page | 2 | Preliminary. Studied in people, but no published study has given it to anyone. 2 human studies where nobody was given it. |
| BimagrumabMetabolic | Investigational, not approved US page | 2 | Moderate. At least one completed trial, and at least 100 people given it. 2 completed trials, 507 people given it. |
| BIO101Muscle & Performance | Investigational, not approved US page | 2 | Moderate. At least one completed trial, and at least 100 people given it. 1 completed trial, 233 people given it. |
| BivamelagonMelanocortin | Investigational, not approved US page | 4 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| BofanglutideMetabolic | Investigational, not approved US page | 5 | Moderate. At least one completed trial, and at least 100 people given it. 5 completed trials, 750 people given it. |
| BrimapitideNootropic & CNS | Investigational, not approved US page | 6 | Moderate. At least one completed trial, and at least 100 people given it. 4 completed trials, 510 people given it. |
| BuntanetapNootropic & CNS | Investigational, not approved US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| CagrilintideMetabolic | Investigational, not approved US page | 5 | Strong. At least two completed trials, and at least 1,000 people given it. 5 completed trials, 5,752 people given it. |
| CagriSemaMetabolic | Investigational, not approved US page | 6 | Strong. At least two completed trials, and at least 1,000 people given it. 3 completed trials, 4,954 people given it. |
| Carbetocin (intranasal)Nootropic & CNS | Investigational, not approved US page | 4 | Moderate. At least one completed trial, and at least 100 people given it. 3 completed trials, 343 people given it. |
| CebranopadolNootropic & CNS | Investigational, not approved US page | 7 | Moderate. At least one completed trial, and at least 100 people given it. 5 completed trials, 300 people given it. |
| CotadutideMetabolic | Investigational, not approved US page | 8 | Strong. At least two completed trials, and at least 1,000 people given it. 6 completed trials, 1,221 people given it. |
| CT-868Metabolic | Investigational, not approved US page | 1 | Moderate. At least one completed trial, and at least 100 people given it. 1 completed trial, 103 people given it. |
| DanuglipronMetabolic | Investigational, not approved US page | 4 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| DapiglutideMetabolic | Investigational, not approved US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, 54 people given it. |
| DavunetideNootropic & CNS | Investigational, not approved US page | 2 | Moderate. At least one completed trial, and at least 100 people given it. 1 completed trial, 313 people given it. |
| DersimelagonMelanocortin | Investigational, not approved US page | 2 | Moderate. At least one completed trial, and at least 100 people given it. 1 completed trial, 165 people given it. |
| DT2216Longevity | Investigational, not approved US page | 4 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, 20 people given it. |
| EcnoglutideMetabolic | Investigational, not approved US page | 3 | Moderate. At least one completed trial, and at least 100 people given it. 3 completed trials, 664 people given it. |
| Efimosfermin alfaMetabolic | Investigational, not approved US page | 3 | Moderate. At least one completed trial, and at least 100 people given it. 2 completed trials, 186 people given it. |
| EfinopegdutideMetabolic | Investigational, not approved US page | 3 | Moderate. At least one completed trial, and at least 100 people given it. 1 completed trial, 145 people given it. |
| EfocipegtrutideMetabolic | Investigational, not approved US page | 2 | Moderate. At least one completed trial, and at least 100 people given it. 2 completed trials, 215 people given it. |
| EfpeglenatideMetabolic | Investigational, not approved US page | 2 | Strong. At least two completed trials, and at least 1,000 people given it. 2 completed trials, 4,076 people given it. |
| EfruxiferminMetabolic | Investigational, not approved US page | 2 | Moderate. At least one completed trial, and at least 100 people given it. 1 completed trial, 181 people given it. |
| ElecoglipronMetabolic | Investigational, not approved US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 2 completed trials, none stating how many people. |
| EloralintideMetabolic | Investigational, not approved US page | 3 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| EnicepatideMetabolic | Investigational, not approved US page | 3 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 2 completed trials, none stating how many people. |
| EnobosarmMuscle & Performance | Investigational; SARMs are not legal dietary ingredients and are on the WADA prohibited list US page | 3 | Moderate. At least one completed trial, and at least 100 people given it. 1 completed trial, 159 people given it. |
| ER-100Longevity | Investigational, not approved US page | 2 | Preliminary. Studied in people, but no published study has given it to anyone. 2 human studies where nobody was given it. |
| ExosomesHealing & Recovery | Investigational, not approved US page | 1 | Moderate. At least one completed trial, and at least 100 people given it. 1 completed trial, 110 people given it. |
| FGF21Metabolic | Investigational, not approved US page | 4 | Moderate. At least one completed trial, and at least 100 people given it. 2 completed trials, 350 people given it. |
| FoselutoclaxLongevity | Investigational, not approved US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 2 completed trials, none stating how many people. |
| GDF15Metabolic | Investigational, not approved US page | 6 | Moderate. At least one completed trial, and at least 100 people given it. 2 completed trials, 313 people given it. |
| GlepaglutideMetabolic | Investigational, not approved US page | 6 | Moderate. At least one completed trial, and at least 100 people given it. 3 completed trials, 230 people given it. |
| GUBamyMetabolic | Investigational, not approved US page | 1 | Preliminary. Studied in people, but no published study has given it to anyone. 1 registered with no result. |
| GYM329Muscle & Performance | Investigational, not approved US page | 3 | Preliminary. Studied in people, but no published study has given it to anyone. 2 human studies where nobody was given it, 1 registered with no result. |
| HalofuginoneLongevity | Investigational, not approved US page | 4 | Preliminary. Studied in people, but no published study has given it to anyone. 3 human studies where nobody was given it, 1 registered with no result. |
| HEC88473Metabolic | Investigational, not approved US page | 1 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| HRS-7535Metabolic | Investigational, not approved US page | 3 | Moderate. At least one completed trial, and at least 100 people given it. 2 completed trials, 235 people given it. |
| IO102-IO103Immune | Investigational, not approved US page | 6 | Moderate. At least one completed trial, and at least 100 people given it. 3 completed trials, 470 people given it. |
| Kisspeptin-10Hormone | Investigational, not approved US page | 8 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 4 completed trials, 44 people given it. |
| Kisspeptin-54Hormone | Investigational, not approved US page | 5 | Moderate. At least one completed trial, and at least 100 people given it. 5 completed trials, 122 people given it. |
| KN069Metabolic | Investigational, not approved US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| LanifibranorMetabolic | Investigational, not approved US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| LarazotideHealing & Recovery | Investigational, not approved US page | 3 | Moderate. At least one completed trial, and at least 100 people given it. 2 completed trials, 526 people given it. |
| LorecivivintHealing & Recovery | Investigational, not approved US page | 3 | Strong. At least two completed trials, and at least 1,000 people given it. 2 completed trials, 1,011 people given it. |
| LOY-002Longevity | Veterinary investigational; not for human use US page | 0 | Preclinical. Animals or cells only among the studies cited here. No human study on this page. 2 animal studies, no human study. |
| MariTideMetabolic | Investigational, not approved US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| MET-233iMetabolic | Investigational, not approved US page | 1 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| MIB-626Longevity | Investigational, not approved US page | 4 | Moderate. At least one completed trial, and at least 100 people given it. 4 completed trials, 107 people given it. |
| MibavademabMetabolic | Investigational, not approved US page | 4 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 2 completed trials, 1 person given it. |
| MitoglitazoneLongevity | Investigational, not approved US page | 4 | Moderate. At least one completed trial, and at least 100 people given it. 2 completed trials, 385 people given it. |
| MonlunabantMetabolic | Investigational, not approved US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| MOTS-c with SS-31Longevity | Investigational, not approved US page | 1 | Preliminary. Studied in people, but no published study has given it to anyone. 1 human study where nobody was given it. |
| NavitoclaxLongevity | Investigational, not approved US page | 4 | Moderate. At least one completed trial, and at least 100 people given it. 2 completed trials, 137 people given it. |
| NemifitideNootropic & CNS | Investigational, not approved US page | 5 | Moderate. At least one completed trial, and at least 100 people given it. 5 completed trials, 177 people given it. |
| NimacimabMetabolic | Investigational, not approved US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 2 completed trials, none stating how many people. |
| NNC0165-1875Metabolic | Investigational, not approved US page | 3 | Moderate. At least one completed trial, and at least 100 people given it. 3 completed trials, 120 people given it. |
| NNC0480-0389Metabolic | Investigational, not approved US page | 3 | Moderate. At least one completed trial, and at least 100 people given it. 1 completed trial, 500 people given it. |
| NNZ-2591Nootropic & CNS | Investigational, not approved US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| NoiiglutideMetabolic | Investigational, not approved US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| NomlabofuspNootropic & CNS | Investigational, not approved US page | 5 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 2 completed trials, 28 people given it. |
| OSK Partial ReprogrammingLongevity | Investigational, not approved US page | 1 | Preliminary. Studied in people, but no published study has given it to anyone. 1 registered with no result. |
| OSKM Cyclic Partial ReprogrammingLongevity | Investigational, not approved US page | 0 | Preclinical. Animals or cells only among the studies cited here. No human study on this page. 6 animal studies, no human study. |
| PegozaferminMetabolic | Investigational, not approved US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| PemvidutideMetabolic | Investigational, not approved US page | 3 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 2 completed trials, none stating how many people. |
| PetrelintideMetabolic | Investigational, not approved US page | 2 | Moderate. At least one completed trial, and at least 100 people given it. 1 completed trial, 493 people given it. |
| PL8177Melanocortin | Investigational, not approved US page | 2 | Preliminary. Studied in people, but no published study has given it to anyone. 2 human studies where nobody was given it. |
| Plasma DilutionLongevity | Investigational, not approved US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 2 completed trials, 42 people given it. |
| RapastinelNootropic & CNS | Investigational, not approved US page | 7 | Strong. At least two completed trials, and at least 1,000 people given it. 5 completed trials, 2,614 people given it. |
| RemternetugNootropic & CNS | Investigational, not approved US page | 2 | Preliminary. Studied in people, but no published study has given it to anyone. 2 human studies where nobody was given it. |
| RetatrutideMetabolic | Investigational, not approved for any indication US page | 11 | Strong. At least two completed trials, and at least 1,000 people given it. 5 completed trials, 1,345 people given it. |
| Retatrutide with cagrilintideMetabolic | Investigational, not approved US page | 4 | Strong. At least two completed trials, and at least 1,000 people given it. 4 completed trials, 4,557 people given it. |
| RibupatideMetabolic | Investigational, not approved US page | 3 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| RisuteganibHealing & Recovery | Investigational, not approved US page | 4 | Moderate. At least one completed trial, and at least 100 people given it. 2 completed trials, 263 people given it. |
| RLS-1496Anti-aging | Investigational, not approved US page | 2 | Preliminary. Studied in people, but no published study has given it to anyone. 1 human study where nobody was given it, 1 registered with no result. |
| RTR242Nootropic & CNS | Investigational, not approved US page | 1 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| Senolytic CAR T cellsImmune | Investigational, not approved US page | 0 | Preclinical. Animals or cells only among the studies cited here. No human study on this page. 3 animal studies, no human study. |
| Senolytic vaccine (anti-GPNMB)Immune | Investigational, not approved US page | 0 | Preclinical. Animals or cells only among the studies cited here. No human study on this page. 3 animal studies, no human study. |
| SG1002Longevity | Investigational, not approved US page | 0 | Preclinical. Animals or cells only among the studies cited here. No human study on this page. 1 animal study, no human study. |
| SRK-439Muscle & Performance | Investigational, not approved US page | 0 | Preclinical. Animals or cells only among the studies cited here. No human study on this page. 1 animal study, no human study. |
| SurvodutideMetabolic | Investigational, not approved US page | 7 | Strong. At least two completed trials, and at least 1,000 people given it. 5 completed trials, 2,034 people given it. |
| Taldefgrobep alfaMuscle & Performance | Investigational, not approved US page | 2 | Preliminary. Studied in people, but no published study has given it to anyone. 2 human studies where nobody was given it. |
| TaspoglutideMetabolic | Investigational, not approved US page | 7 | Strong. At least two completed trials, and at least 1,000 people given it. 3 completed trials, 2,181 people given it. |
| TelaglenastatLongevity | Investigational, not approved US page | 5 | Moderate. At least one completed trial, and at least 100 people given it. 3 completed trials, 513 people given it. |
| TesofensineMetabolic | Investigational, not approved US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| Thymosin Alpha-1Immune | Not fully approved; orphan-drug designation only US page | 3 | Strong. At least two completed trials, and at least 1,000 people given it. 2 completed trials, 1,204 people given it. |
| TrevogrumabMuscle & Performance | Investigational, not approved US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| TrontinemabNootropic & CNS | Investigational, not approved US page | 3 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 2 completed trials, none stating how many people. |
| UBT251Metabolic | Investigational, not approved US page | 2 | Limited. Someone has been given it and a result was published, but fewer than 100 people. 1 completed trial, none stating how many people. |
| UBX0101Longevity | Investigational, not approved US page | 4 | Moderate. At least one completed trial, and at least 100 people given it. 1 completed trial, 183 people given it. |
| VK2735Metabolic | Investigational, not approved US page | 3 | Strong. At least two completed trials, and at least 1,000 people given it. 3 completed trials, 4,650 people given it. |
Where to go from here
Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.